DiaMedica Therapeutics Inc. Research and Development Expense
DiaMedica Therapeutics Inc. (DMAC) reported Research and Development Expense of $8.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- DiaMedica Therapeutics Inc. research and development expense for the quarter ending 2026-06-30 was $8.15M, a 40.04% increase year-over-year.
- DiaMedica Therapeutics Inc. research and development expense for the quarter ending 2026-03-31 was $7.99M, a 41.21% increase year-over-year.
- DiaMedica Therapeutics Inc. research and development expense for the quarter ending 2025-12-31 was $6.70M, a 3.54% increase year-over-year.
- DiaMedica Therapeutics Inc. research and development expense for the quarter ending 2025-09-30 was $6.44M, a 29.18% increase year-over-year.
- DiaMedica Therapeutics Inc. research and development expense for fiscal 2025 was $24.61M, a 29.16% increase from fiscal 2024.
- DiaMedica Therapeutics Inc. research and development expense for fiscal 2024 was $19.06M, a 45.36% increase from fiscal 2023.
- DiaMedica Therapeutics Inc. research and development expense for fiscal 2023 was $13.11M, a 67.24% increase from fiscal 2022.
- DiaMedica Therapeutics Inc. research and development expense for fiscal 2022 was $7.84M, a 10.56% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $8.15M 10-Q · filed 2026-08-10 | $16.14M 10-Q · filed 2026-08-10 | $22.84M derived: sum of 3 quarters · filed 2026-08-10 | $29.28M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2026-03-31 | $7.99M 10-Q · filed 2026-05-06 | $14.69M derived: sum of 2 quarters · filed 2026-05-06 | $21.12M derived: sum of 3 quarters · filed 2026-05-06 | $26.95M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-12-31 | $6.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $13.14M derived: sum of 2 quarters · filed 2026-03-30 | $18.96M derived: sum of 3 quarters · filed 2026-08-10 | $24.61M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $6.44M 10-Q · filed 2025-11-12 | $12.26M derived: sum of 2 quarters · filed 2026-08-10 | $17.91M 10-Q · filed 2025-11-12 | $24.39M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-06-30 | $5.82M 10-Q · filed 2026-08-10 | $11.48M 10-Q · filed 2026-08-10 | $17.95M derived: sum of 3 quarters · filed 2026-08-10 | $22.93M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-03-31 | $5.66M 10-Q · filed 2026-05-06 | $12.13M derived: sum of 2 quarters · filed 2026-05-06 | $17.11M derived: sum of 3 quarters · filed 2026-05-06 | $21.04M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $6.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $11.45M derived: sum of 2 quarters · filed 2026-03-30 | $15.38M derived: sum of 3 quarters · filed 2026-03-30 | $19.06M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $4.98M 10-Q · filed 2025-11-12 | $8.91M derived: sum of 2 quarters · filed 2025-11-12 | $12.59M 10-Q · filed 2025-11-12 | $16.26M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | $3.93M 10-Q · filed 2025-08-12 | $7.60M 10-Q · filed 2025-08-12 | $11.28M derived: sum of 3 quarters · filed 2025-08-12 | $14.55M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | $3.68M 10-Q · filed 2025-05-13 | $7.35M derived: sum of 2 quarters · filed 2025-05-13 | $10.63M derived: sum of 3 quarters · filed 2025-05-13 | $13.17M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $3.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $6.95M derived: sum of 2 quarters · filed 2025-03-17 | $9.49M derived: sum of 3 quarters · filed 2025-03-17 | $13.11M 10-K · filed 2025-03-17 | ||||
| 2023-09-30 | $3.27M 10-Q · filed 2024-11-13 | $5.82M derived: sum of 2 quarters · filed 2024-11-13 | $9.43M 10-Q · filed 2024-11-13 | $11.70M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $2.54M 10-Q · filed 2024-08-07 | $6.16M 10-Q · filed 2024-08-07 | $8.43M derived: sum of 3 quarters · filed 2024-08-07 | $10.07M derived: sum of 4 quarters · filed 2024-08-07 | ||||
| 2023-03-31 | $3.62M 10-Q · filed 2024-05-08 | $5.89M derived: sum of 2 quarters · filed 2024-05-08 | $7.53M derived: sum of 3 quarters · filed 2024-05-08 | $9.48M derived: sum of 4 quarters · filed 2024-05-08 | ||||
| 2022-12-31 | $2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $3.91M derived: sum of 2 quarters · filed 2024-03-19 | $5.87M derived: sum of 3 quarters · filed 2024-03-19 | $7.84M 10-K · filed 2024-03-19 | ||||
| 2022-09-30 | $1.64M 10-Q · filed 2023-11-13 | $3.60M derived: sum of 2 quarters · filed 2023-11-13 | $5.57M 10-Q · filed 2023-11-13 | $7.44M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $1.96M 10-Q · filed 2023-08-14 | $3.93M 10-Q · filed 2023-08-14 | $5.80M derived: sum of 3 quarters · filed 2023-08-14 | $8.13M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $1.97M 10-Q · filed 2023-05-15 | $3.85M derived: sum of 2 quarters · filed 2023-05-15 | $6.18M derived: sum of 3 quarters · filed 2023-05-15 | $8.33M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $4.20M derived: sum of 2 quarters · filed 2023-03-28 | $6.36M derived: sum of 3 quarters · filed 2023-03-28 | $8.77M 10-K · filed 2023-03-28 | ||||
| 2021-09-30 | $2.33M 10-Q · filed 2022-11-09 | $4.49M derived: sum of 2 quarters · filed 2022-11-09 | $6.89M 10-Q · filed 2022-11-09 | $9.99M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $2.16M 10-Q · filed 2022-08-11 | $4.56M 10-Q · filed 2022-08-11 | $7.66M derived: sum of 3 quarters · filed 2022-08-11 | $9.82M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $2.41M 10-Q · filed 2022-05-04 | $5.50M derived: sum of 2 quarters · filed 2022-05-04 | $7.66M derived: sum of 3 quarters · filed 2022-05-04 | $9.26M derived: sum of 4 quarters · filed 2022-05-04 | ||||
| 2020-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $5.25M derived: sum of 2 quarters · filed 2022-03-14 | $6.86M derived: sum of 3 quarters · filed 2022-03-14 | $8.21M 10-K · filed 2022-03-14 | $8.31M 10-K · filed 2021-03-10 | |||
| 2020-09-30 | $2.16M 10-Q · filed 2021-11-10 | $2.18M 10-Q · filed 2020-11-04 | $3.76M derived: sum of 2 quarters · filed 2021-11-10 | $5.11M 10-Q · filed 2021-11-10 | $5.19M 10-Q · filed 2020-11-04 | $6.91M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $1.60M 10-Q · filed 2021-08-11 | $1.63M 10-Q · filed 2020-08-11 | $2.95M 10-Q · filed 2021-08-11 | $3.01M 10-Q · filed 2020-08-11 | $4.75M derived: sum of 3 quarters · filed 2021-08-11 | $6.37M derived: sum of 4 quarters · filed 2021-08-11 | ||
| 2020-03-31 | $1.35M 10-Q · filed 2021-05-05 | $1.38M 10-Q · filed 2020-05-13 | $3.15M derived: sum of 2 quarters · filed 2021-05-05 | $4.77M derived: sum of 3 quarters · filed 2021-05-05 | $6.64M derived: sum of 4 quarters · filed 2021-05-05 | |||
| 2019-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | $3.42M derived: sum of 2 quarters · filed 2021-03-10 | $5.29M derived: sum of 3 quarters · filed 2021-03-10 | $7.90M 10-K · filed 2021-03-10 | ||||
| 2019-09-30 | $1.62M 10-Q · filed 2020-11-04 | $3.49M derived: sum of 2 quarters · filed 2020-11-04 | $6.10M 10-Q · filed 2020-11-04 | $7.55M derived: sum of 4 quarters · filed 2020-11-04 | ||||
| 2019-06-30 | $1.87M 10-Q · filed 2020-08-11 | $4.48M 10-Q · filed 2020-08-11 | $5.93M derived: sum of 3 quarters · filed 2020-08-11 | $7.14M derived: sum of 4 quarters · filed 2020-08-11 | ||||
| 2019-03-31 | $2.61M 10-Q · filed 2020-05-13 | $4.06M derived: sum of 2 quarters · filed 2020-05-13 | $5.27M derived: sum of 3 quarters · filed 2020-05-13 | $6.34M derived: sum of 4 quarters · filed 2020-05-13 | ||||
| 2018-12-31 | $1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-23 | $2.66M derived: sum of 2 quarters · filed 2020-03-23 | $3.73M derived: sum of 3 quarters · filed 2020-03-23 | $4.52M 10-K · filed 2020-03-23 | ||||
| 2018-09-30 | $1.21M 10-Q · filed 2019-11-13 | $2.28M derived: sum of 2 quarters · filed 2019-11-13 | $3.07M 10-Q · filed 2019-11-13 | |||||
| 2018-06-30 | $1.07M 10-Q · filed 2019-08-13 | $1.86M 10-Q · filed 2019-08-13 | ||||||
| 2018-03-31 | $791.00K 10-Q · filed 2019-05-13 | |||||||
| 2017-12-31 | $3.21M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |